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Abstract
Background Pulmonary pleomorphic carcinoma (PPC) is
a rare type of lung cancer characterized by the poor
response to conventional chemotherapy and subsequent
disappointing outcomes. Therefore, it is paramount to
delineate the molecular characteristics of this disease
entity.
Methods In this study, we retrospectively examined the
surgical specimens of 61 patients who underwent lung
surgery. Mutational or gene ampliﬁcation statuses of epi-
dermal growth factor receptor (EGFR), k-ras, c-kit, c-met,
and ﬁbroblast growth factor receptor (FGFR) were exam-
ined using genomic DNA sequencing, real-time PCR and/
or ﬂuorescence in situ hybridization (FISH).
Results Themedianagewas61 years,and50patientswere
men and 11 were women. In the histologic review of epi-
thelial component, adenocarcinoma were in 44 cases (72%),
squamous cell carcinoma in 15 (25%) and large cell carci-
noma in 2 patients (3%). Overall, 30 cases (49%) had any
molecular alterations. Nine patients (15%) possessed EGFR
deletion in exon 19 (n = 8) or L858R mutations in exon 21
(n = 1), while 3 other cases having atypical EGFR muta-
tions.Sixpatients(9.8%)hadk-rasmutationsinexon12,and
3 had c-kit mutations. High gene copy number of c-met was
found in 11 patients (18.0%) and that of FGFR was in 6
patients (9.8%). No signiﬁcant relationships were identiﬁed
among the occurrence and type of mutations and patient
survival or any other clinicopathological variables.
Conclusions Given the diverse repertoire of mutational
proﬁles observed in PPC samples, clinical trials based on
accurate cancer-genotyping should be considered as a legiti-
matetreatmentschemeforthisrarediseaseentityinthefuture.
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Background
Pulmonary pleomorphic carcinoma (PPC) is a rare pul-
monary epithelial malignant tumor that represents
0.1–0.4% of all malignant tumors of the lung (Ito et al.
2010; Pelosi et al. 2010). According to the World Health
Organization’s classiﬁcation of lung tumors, PPC is a
group of poorly differentiated tumors characterized path-
ologically by a combination of epithelial and mesenchymal
elements and is deﬁned as either non-small-cell carcinoma
combined with at least 10% of neoplastic spindle or giant
cell (Beasley et al. 2005).
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tumors have not been well known due to a small series of
data. In general, however, PPC has been reported to occur
predominantly in men who smoke heavily, with an average
age at diagnosis of 60 years, and is characterized by the
poor response to conventional chemotherapy and sub-
sequent disappointing clinical outcomes (Bae et al. 2007;
Fishback et al. 1994; Hong et al. 2009; Mochizuki et al.
2008; Rossi et al. 2003).
Compared with other common epithelial cancers, cur-
rent knowledge about the biology of PPC is very limited,
and as a result, little is known about its molecular pathol-
ogy. Some genetic alterations appear frequently in non-
small-cell lung cancer and drugs targeting these genetic
pathways are clinically available. Some selected genes,
such as epidermal growth factor receptor (EGFR),k -ras,
p53, etc., have been analyzed in small cohorts of PPC
patients (Arita et al. 2005; Blaukovitsch et al. 2006; Itali-
ano et al. 2009; Kaira et al. 2010; Pelosi et al. 2004; Ushiki
et al. 2009). A previous study reported that EGFR mutation
was positive in about 20% of PPC, which give some chance
to apply target agents to PPC (Kaira et al. 2010). To date,
however, extensive molecular researches on PPC have
been largely hampered by the rarity of the tumor and a lack
of established cell lines and animal models.
To gain more extensive insights into the oncogenic
nature of PPC, we have characterized the mutational or
ampliﬁcation status of several well-known oncogenic tar-
get genes, such as EGFR mutation, K-ras mutation, c-kit
mutation, c-met ampliﬁcation, and ﬁbroblast growth factor
receptor (FGFR) ampliﬁcation in 61 surgically resected
PPC samples. The target genes were selected based on the
possibility that these are the most frequent genes in
NSCLC and are correlated with clinical outcomes of
available target agents (Han et al. 2006; Heinrich et al.
2002; Ma et al. 2003; Noble et al. 2004).
Materials and methods
Patient samples
Tumors specimens from 61 patients with PPC who
underwent surgical resection at Samsung Medical Center
from January 1995 to March 2009 were identiﬁed. All
tumors were retrieved from parafﬁn-embedded blocks.
All slides from the lung resection specimens were
reviewed by two expert pathologists (JHH and YLC). In
all cases, the diagnosis of PPC was established according
to the 2004 World Health Organization’s classiﬁcation of
tumors. Clinical staging was determined according to the
6th International Association for the Study of Lung
Cancer.
Biomarker analysis
Biomarker analyses were retrospectively performed on
formalin ﬁxed parafﬁn-embedded (FFPE) archival tumor
tissues after pathologic review. Sections from tissue blocks
containing more than 80% representative malignant cells
were used for all analyses.
The mutational analyses of EGFR (exon 18–21), k-ras
(exon 2, 3), and c-kit (exon 9, 11, 13, and 17) were per-
formed using directional sequencing of PCR fragments
ampliﬁed from genomic DNA. The results were marked as
mutation-positive if a mutation was detected in both the
forward and reverse DNA strand.
Gene copy numbers of c-met per cell were determined
using ﬂuorescence in situ hybridization (FISH) with the
KreathechPoseidonMET/SE17-probekit.Copynumbersof
FGFR were determined using bacterial artiﬁcial chromo-
some clones #669(10q26.13) and #493(10q26.13) contain-
ing FGFR2 (Macrogen, Seoul, Korea) labeled with
rhodamine ﬂuorescent dye. The centromere clones labeled
with FITC ﬂuorescent dye were #5331, #5344, and #46
(10q12.1).Brieﬂy,forFISHprocedures,4-lm-thicksections
of FFPE tissue blocks were deparafﬁnized, dehydrated, and
immersed in 0.2N HCl, and then boiled in a microwave in
citratebuffer(pH6.0).Theprobemixtureswereaddedtothe
slides, and then the slides were incubated in a humidiﬁed
atmosphere at 73C for 5 min to denature the probe and
target DNA, after which they were sequentially cooled and
incubated at 37C for 19 h to allow for hybridization. The
slides were then washed with 0.4 9 SSc/0.3% NP-40 for
2 min at room temperature, followed by 2 9 SSc/0.1% NP-
40 for 5 min at 73C. For the nuclei counterstaining, 4,6-
diamidini-2-phenylindone (DAPI) and anti-face compound
(p-phenylenediamine) were added. Signals for each probe
were evaluated under a microscope equipped with a triple-
pass ﬁlter (DAPI/Green/Orange; Vysis). At least 100 tumor
cell nuclei were counted per case. FISH analysis was per-
formedindependentlybytwopathologistswhowereblinded
to the patients’ clinical characteristics and to all other
molecular variables.
High gene copy number was deﬁned as high polysomy
(Ccutoff copies in[40% of cells using Colorado system)
or gene ampliﬁcation (presence of tight gene clusters; a
gene: chromosome ratio per cell C2o rC15 copies of target
probes per cell in C10% of cells analyzed).
All biomarkers were independently determined with
blinding to clinical outcome prior to any statistical
analysis.
Statistical methods
All patients were included in the statistical calculations.
Follow-up was obtained in all cases and was ended on
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123November 1, 2009. Categorical variables were compared
using the Chi-squared test. The overall survival (OS) was
the interval from lung surgery to death or the last follow-
up. Survival was assessed using the Kaplan–Meier method.
Results were considered signiﬁcant at the 0.05 level. Sta-
tistical analyses were performed using the SPSS software
program, version 18.0.
Results
Patient characteristics and survival
A total of 61 PPC specimens were available, and the
clinical characteristics of patients are described in Table 1.
The median age was 61.4 years (range, 36.0–85.0 years),
and the male (n = 50)/female (n = 11) ratio was 5:1.
Thirteen patients were current smokers, 27 patients were
ex-smokers, and 21 had never been smokers. Tumor size
ranged between 14 and 153 mm (median, 46 mm).
All patients underwent curative resection except three
patients who received palliative surgery for metastatic
disease. Pathological stages were stage I in 26 patients
(41.0%), stage II in 19 (31.1%), stage III in 13 (21.3%),
and stage IV in 3 patients. The median survival time was
33.9 months (95% CI, 0.0–69.3 months).
Of the 61 patients, 22 (36%) relapsed after surgery with
16 recurrences in distant sites. The other 39 patients
(63.9%) experienced no recurrence at the time of analysis,
including 11 patients who died of non-cancer-related dis-
ease (pneumonia, heart disease, etc.).
Among the various clinical parameters, univariate
analyses indicated that early disease stage (P\0.001),
good ECOG performance status (P\0.001), and receipt of
adjuvant radiotherapy (P = 0.012) or palliative chemo-
therapy (P\0.001) were related with signiﬁcantly
increased OS. The multivariate analysis showed that clin-
ical parameters including stage, ECOG performance status,
and receipt of palliative chemotherapy were independent
prognostic factors in terms of OS (Table 2).
Epithelial/mesenchymal components and survival
In the histologic review of malignant epithelial compo-
nents, adenocarcinoma were in 44 cases (72%), squa-
mous cell carcinoma in 15 (25%), and large cell
carcinoma in 2 patients (3%). For the mesenchymal
components, 44 cases (72%) had spindle cell tumors and
17 (28%) had giant cell tumors. Therefore, 5 subgroups
were categorized according to the epithelial/mesenchymal
component: adenocarcinoma/spindle cell tumors were in
29 cases (48%), adenocarcinoma/giant cell tumors in 15
(25%), squamous cell carcinoma/spindle cell tumors in
13 (21%), squamous cell carcinoma/giant cell tumors in
2 (3%), and large cell carcinoma/spindle cell tumors in 2
cases (3%).
The median OS in patients with adenocarcinoma
(n = 44) and non-adenocarcinoma (n = 17) component
were 30.2 months (95% CI, 0.0–70.8 months) and
33.9 month (95% CI, 13.2–54.6 months), respectively,
and there was no statistical difference (P = 0.86).
Patients with spindle cell tumor component (n = 44)
showed longer median OS (38.9 months: 95% CI cannot
be calculated) than those with giant cell tumor compo-
nent (24.7 months: 95% CI, 5.9–43.5 months), but the
difference was short of the statistical signiﬁcance
(P = 0.37). In the analyses of 5 subgroups categorized
by the epithelial/mesenchymal component, there was no
signiﬁcant survival difference among 5 subgroups (data
not shown).
Table 1 Patients’ characteristics (N = 61)
Number of patients (%)
Median age, years (range) 61.4 (36.0–85.0)
Sex
Male 50 (82.0)
Female 11 (18.0)
Smoking status
Never smoker 21 (34.4)
Ex-smoker 27 (44.2)
Current smoker 13 (21.3)
Performance status (ECOG)
0 29 (47.5)
1 29 (47.5)
2 3 (4.9)
Adjuvant chemotherapy 14 (23.0)
Adjuvant radiotherapy 10 (16.4)
Surgery type
Pneumonectomy 5 (8.2)
Bilobectomy 10 (16.4)
Lobectomy 43 (70.5)
Others 3 (4.9)
Stage
I 26 (41.1)
II 19 (31.1)
III 13 (21.3)
IV 3 (4.9)
Recurrence
Yes 22 (36.1)
No 39 (43.9)
Median follow-up (months) 63.5 (8.0–165.6)
OS (months) 33.9 (0.0–69.3)
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Of the 61 clinical tumor specimens proﬁled, 30 cases
contained any genetic mutations or increased gene dosages.
The molecular proﬁles, combined with the histologic
review of epithelial/mesenchymal components and smok-
ing status, of these 30 cases were shown in Table 3.
Somatic EGFR mutations were found in 12 out of 61
patients (19.6%). Nine patients (14.8%) possessed well-
established activating EGFR mutation signatures, with
exon 19 partial deletions in 8 patients and an exon 21
L858R substitution mutation in one patient. The other three
mutations resided in either exon 20 or exon 21, the tar-
getabilities by clinically available EGFR inhibitors of
which are currently not well established. From the proﬁling
analysis of the tumor specimens, we identiﬁed 6 patients
who possessed k-ras mutations. A heterozygous G to T
substitution at nucleotide position 34 (Gly to Cys) was
Table 2 Univariate and multivariate analysis for overall survival
Variables Univariate analysis Multivariate analysis
Survival (mon) 95% CI P-value Survival (mon) 95% CI P-value
Age
\61.4 NA NA 0.157
C61.4 30.2 9.3–51.2
Sex
Male 38.9 7.8–70.1 0.462
Female 18.0 1.6–34.4
Smoking
Never smoker 18.0 0.0–37.0 0.163
Ex-smoker NA NA
Current smoker 38.9 0.0–84.8
Performance status (ECOG)
0N A N A \0.001 2.586 1.304–5.128 0.007
1 24.7 13.5–35.9
2 2.4 1.9–2.8
Adjuvant chemotherapy
No 30.2 14.4–46.1 0.642
Yes NA NA
Adjuvant radiotherapy
No 94.7 14.2–175.1 0.012
Yes 9.5 4.1–14.9
Surgery
Pneumonectomy 18.1 0.0–43.1 0.218
Bilobectomy 12.0 0.0–27.7
Lobectomy 94.7 12.2–177.1
Others NA NA
Stage
1N A N A \0.001 1.577 1.100–2.261 0.013
2 33.9 17.9–49.9
3 7.8 0.0–15.5
4 8.9 4.9–12.9
Recurrence
No 94.7 NA \0.001
Yes 12.0 2.3–21.7
Palliative chemotherapy
No 94.7 0.9–188.5 \0.001 0.393 0.173–0.859 0.020
Yes 9.5 3.9–15.2
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sponded to the k-ras amino acid 12 substitution mutation,
including a heterozygous G to T substitution at nucleotide
position 35 (Gly to Val), a G to A substitution at 35 (Gly to
Asp), and a G to C substitution at 35 (Gly to Ala). Inter-
estingly, one patient (patient number 36) with k-ras
mutation (c.35G[;p Gly12Ala) also had EGFR mutation
(exon 19 deletion). In the analysis of c-kit, we identiﬁed 3
patients who possessed c-kit mutations.
Further, we analyzed the gene dosage statuses of FGFR
and c-met using ﬂuorescence in situ hybridization (FISH).
The median gene dosage of FGFR was 1.06 (range,
0.33–5.76), and, with the cutoff value set at 2 points, six
patients showed increased FGFR gene dosage (Fig. 1). In
the case of c-met, 11 patients demonstrated increased gene
dosage; c-met ampliﬁcation was observed in one patient
and high polysomy was seen in 10 patients (Fig. 2). There
was no statistically signiﬁcant correlation between high
gene copy number of the c-met gene and patient survival.
There were no statistically signiﬁcant correlations
between the type of gene mutations and overall survival
(Table 4).
Table 3 Molecular proﬁles in PPCs (N = 30)
Sample
No
EGFR KRAS c-kit c-met FGFR
2 High polysomy
4 High polysomy
7 Exon 19 c.2240-2257del Exon 9 p.Thr488Ala
8 Exon 19 c.2240-2257del
9 High polysomy
11 Exon 21 p.Leu858Arg
15 Exon 19c.2240-2257del
Exon 21 c.2561insC High polysomy
16 High polysomy
17 High polysomy
21 High polysomy
25 c.35G[T;p.Gly12Val
26 Exon 20 p.Arg776Cys High polysomy
28 c.34G[T;p.Gly12Cys
32 c.34G[T;p.Gly12Cys
34 Exon 20 c.2370_2371insAG,
c.2298G[C(p.Ala800Pro)
36 Exon 19 c.2240-2257del c.35G[A;p.Gly12Asp ?
37 Exon 19 c.2240-2257del
38 High polysomy
40 High polysomy
41 c.35G[C;p.Gly12Ala
42 Exon 19 c.2240-2257del Exon 9 p.Pro468Leu,
p.Val489Asp
?
46 ?
47 Exon 19 c.2240-2257del Exon 9
p.Phe483Leu,p.Cys491Arg
50 Exon 19 c.2240-2257del
51 ?
52 c.34G[T;p.Gly12Cys
55 Exon 20
p.Ser768_Asp770dupSerValAsp
58 Ampliﬁcation
59 ?
60 ?
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in association with clinicopathologic factors
Of 44 tumors with adenocarcinoma components, 6 (13.6%)
had activating EGFR mutations, and 3 (17.6%) of 17
tumors with non-adenocarcinoma component had activat-
ing EGFR mutations. Therefore, the distribution of acti-
vating EGFR mutation was not associated with the type of
malignant epithelial components (P = 0.69). The distri-
bution of activating EGFR mutation was also insigniﬁ-
cantly associated with other clinicopathologic factors, such
as gender (all 9 in men, P = 0.13), smoking status (never-
vs ever-smoker, P = 0.94), and the type of mesenchymal
malignant components (spindle cell vs giant cell,
P = 0.23).
Discussion
PPC is a rare aggressive disease characterized by a high rate
ofdistantrecurrenceafterinitialsurgeryforlocalizeddisease
(Hong et al. 2009). There is presently no available data
indicating the optimal management of patients with this
advanced disease. In particular, the role of chemotherapy
remains unclear, and these patients are often treated
according to the results of trials of enrolled patients with
NSCLC, such as squamous cell carcinoma or adenocarci-
noma. Many targeted agents are widely used for the treat-
ment of patients with advanced NSCLC. However, whether
these drugs have some activity in PPC is not yet clear.
EGFR, K-ras, c-met, and FGFR are receptor tyrosine
kinases (RTKs) frequently activated by gene ampliﬁcation
Fig. 1 Fluorescence in situ
hybridization (FISH) assay for
the detection of the FGFR a No
ampliﬁcation of the FGFR
b Ampliﬁcation of the FGFR
Fig. 2 FISH assay for the
detection of c-Met a No
ampliﬁcation of the c-Met
b High polysomy of the c-met
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cancer. EGRF and K-ras have been already well-known
target genes in NSCLC. The occurrence of MET ampliﬁ-
cation and EGFR/K-ras mutation might be mutually
exclusive suggesting several distinct mechanisms in the
development of NSCLC (Onitsuka et al. 2010). FGFR-
mediated signals in cooperation with those transmitted by
EGFR are involved in growth and survival of human
NSCLC cells and should be considered as targets for
combined therapeutic approaches (Fischer et al. 2008).
Various RTKs have come into the focus of therapeutic
considerations since they can be targeted by pharmaceuti-
cal intervention and because tumors bearing oncogenic
RTK mutations generally show a good response to targeted
therapy.
To gain further insight into the clinical targetabilities of
PPCs, we performed a molecular analysis of 61 resected
PPCs. Previous studies have analyzed only a small number
of tumors and have mostly focused on histological and
clinical characteristics of this rare disease entity. Thus, this
study is one of the ﬁrst attempts to genetically characterize
PPCs, with the underlying premise of rapidly extending
this knowledge to clinical oncology practices. Several
characteristics of PPCs emerged from these analyses.
Mutational analysis of PPCs demonstrated that about half
of the patients possess one or multiple combinations of the
above ﬁve genetic abnormalities. The activating EGFR
mutations were seen in 9 patients (14.8%) (19.8%,
including 3 atypical mutations), whereas k-ras oncogenic
mutations were identiﬁed in six patients (9.8%); the EGFR
positive rates is largely consistent with that observed for
other lung cancers in East Asians (Ahn et al. 2008), and
with the recently evaluated value (18%, 3 out of 17) in
Japanese PPC patients (Kaira et al. 2010). However, the
mutation rate found here is in contrast to results of Italiano
et al., who reported that PPCs are characterized by a lack of
EGFR mutation and a high rate of k-ras mutations (Italiano
et al. 2009; Pelosi et al. 2004). It is well established that
ethnic differences heavily affect EGFR etiology in lung
cancer, and PPCs might be under similar ethnic inﬂuences
in their ontogeny. In the present study, however, the dis-
tribution of EGFR mutation was not in line with the well-
established phenomena. Namely, the EGFR mutations were
detected, irrespective of clinicopathologic factors such as
the component of adenocarcinoma, smoking status, and
gender. Although this distribution of EGFR mutation can
be explained in part by the speciﬁc characteristics of PPC,
it should be cautious to interpret these data due to the small
number of samples.
In the case of c-met, 11 patients demonstrated increased
gene dosage; a c-met ampliﬁcation and 10 high polysomies
were detected using FISH. The c-met receptor tyrosine
kinase has been associated with NSCLC as well as with
SCLC (Chang et al. 2001; Jagadeeswaran et al. 2007;
Maulik et al. 2002), suggesting that the c-met receptor may
play an important role in cellular fate changes, including
the epithelial to mesenchymal transition (Kubo et al. 2009;
Salgia 2009). Increased c-met gene dosage was observed to
be largely independent of EGFR and k-ras mutations in
PPCs, positioning its blockade as an interesting mono-
therapy target.
Remarkably, the ﬁve genetic factors we have chosen to
study in the analysis resulted in an unexpectedly high ratio
of PPC samples detected with this deﬁned probe set of
genetic alterations. The fact that these patients who possess
druggable or actionable molecular targets should be con-
sidered as candidates for mono or combinational targeted
cancer therapy leads to an immediate clinical implication
that warrants further validation in prospective clinical tri-
als. Especially, EGFR mutation can be a possible predic-
itive marker for geﬁtinib or erlotinib and it is important to
investigate where EGFR-TKI is effective for advanced
PPC patients.
The molecular origin of PPC still remains largely
obscure. It is the deﬁnition of a disease unit based on the
histological observation, and whether there exists a sin-
gular genetic event leading to the emergence of this rare
tumor type is still unknown. It is possible that a minute
proportion of non-small-cell lung cancer will undergo a
series of secondary genetic changes during the course of
tumor evolution, reprogramming the cellular fates of pri-
mary tumors and propelling rare transitions in cellular fate
through transdifferentiation or dedifferentiation. This re-
directed cellular fate speciﬁcation may culminate in
Table 4 Association of EGFR, KRAS, c-kit, C-met, and FGFR
mutations with overall survival using univariate analysis
Molecular markers Univariate analysis
Survival (months) 95% CI P-value
EGFR
No 30.2 0.0–70.1 0.879
Yes 33.9 NA
k-ras
No 33.9 0.0–71.4 0.348
Yes 10.1 0.0–26.8
c-kit
No 30.2 13.6–46.8 0.575
Yes NA NA
FGFR
No 33.9 0.0–72.3 0.744
Yes 10.1 NA
c-Met
No 26.0 9.2–42.8 0.374
Yes 94.7 12.0–177.3
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samples. The mutation proﬁling study presented here
indicates that, at least, the oncogenic origins of this cancer
type may be rather diverse, encompassing several well-
known pulmonary oncogenic genetic factors.
The limitation of this study, as with many other
mutation proﬁling studies, is that we can only detect a
set of mutations in a subset of oncogenes with pre-
established oncogenecity. Thus, other sets of mutations
critical to the oncogenic process of PPCs might be
missing in the analysis. Moreover, the percentages of
these mutations detected from this preliminary screening
that correspond to oncogenic or driver mutations need to
be determined in future prospective studies. Given the
rarity of this disease type, it will take a signiﬁcant
amount of time to accumulate sufﬁcient clinical cases to
properly determine the beneﬁt the patients will experi-
ence from prospective oncogeno-chemo trials compared
with that of histology-based conventional chemothera-
peutics. To resolve this issue, further systemic and
hypothesis-driven or a priori knowledge-free genomics-
guided patient stratiﬁcation is warranted in the laboratory
to help more accurately describe each patient’s
onco-genetics map. Until then, however, this preliminary
attempt to characterize the mutational space of PPCs,
previously thought to be an extremely malignant cancer
type, will provide measurable molecular guidance to the
alternative molecular treatment of this rare disease.
In summary, we have characterized the mutational sta-
tuses of several well-known oncogenic targets in a large set
of PPC tumors. Given the diverse repertoire of mutational
proﬁles observed from PPC samples, clinical trials based
on accurate cancer-genotyping should be considered as a
legitimate treatment scheme for this rare and hard-to-cure
disease entity.
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